Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025584 · ClinicalTrials.gov registry record · Phase 2
PS-341 in Treating Women With Metastatic Breast Cancer
A Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00025584 is a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00025584, a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025584
The ClinicalTrials.gov registry entry for NCT00025584 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00025584 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00025584 about?
NCT00025584 is a clinical study titled "PS-341 in Treating Women With Metastatic Breast Cancer". PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
What is the current status of trial NCT00025584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-08.
What conditions does trial NCT00025584 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT00025584?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00025584?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025584 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
COMPLETED · Phase 2
-
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.